Introduction:
Breast cancer remains a major health burden affecting the lives of millions of women the world over. International Agency for Research on Cancer (IARC) data reported that 1.7 million women were diagnosed with breast cancer worldwide in 2012. In India, the incidence of breast cancer is on the rise (1), and has surpassed cervical cancer in the metropolitan cities.
The chances of disease-free survival of breast cancer patients have increased over the last few decades; however, this is applicable only if the disease is diagnosed at an early stage and is limited to the primary organ site (2) . Once breast cancer metastasizes to other organs, the therapeutic options are very limited and the success rate of managing such patients in the clinics is poor. Therefore, there is an urgent need for the development of mechanism-based, targeted therapeutic strategies with improved outcomes for the treatment of aggressive cancers.
Breast cancer is a heterogeneous disease that can be classified using a variety of clinical and pathological features. The status of three hormone receptors -estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) -is routinely used to categorize breast cancers and they also serve as predictive biomarkers to select specific adjuvant therapies (3). ER and /or PR positive tumors are administered with hormone therapy and in general show good survival rates. Similarly, HER2 positivity is useful for selecting targeted therapy with monoclonal antibody (trastuzumab) against HER2 (4) . In contrast, the triple negative breast cancer (TNBC) subtype, that accounts for ~15% of breast cancer cases, is characterized by the absence of ER, PR, and HER2. As a group, these tumors exhibit an aggressive clinical phenotype with early development of visceral metastases and a poor long-term prognosis (5) . Thus, the TNBCs constitute an imperative clinical challenge, as they do not respond to endocrine treatment and currently lack any targeted therapies.
Notch signaling is an evolutionary conserved pathway and plays a key role in various cellfate decisions throughout embryonic development and later in adult homeostasis (6) . There are four Notch receptors and five ligands; interactions between Notch receptor and ligand results in proteolytic cleavages finally leading to the release of the Notch intracellular domain (NICD) that translocates to the nucleus and functions as a transcription factor (7) . Aberrant Notch signaling has been associated with various cancers including breast cancers (8, 9) .
High level expression of Notch1 is an early event during breast carcinogenesis, and together with a ligand Jagged1, is predictive of poor overall survival (10) . We have previously demonstrated overexpression of several Notch receptors and ligands in breast cancers, as well as Notch activation in early precursors and invasive ductal carcinomas (11) . Recent reports have associated Notch signaling with TNBCs (12) and aggressive phenotypes (13) . Further, recent studies have revealed the requirement of Notch signaling for the maintenance of breast cancer stem-like cells (14, 15) . Thus, Notch signaling has been associated with both the development and progression of breast cancers, suggesting that inhibition of Notch signaling may be beneficial for breast cancer treatment (16) .
The oncogenic functions of Notch signaling in breast cancers may be mediated through its cross talks with other signaling pathways. For example, cross talk between Notch and estrogen receptor signaling has been documented in breast cancers (17) . Further, cross talk between ErbB1/2 and Notch signaling has been shown in DCIS, and combined inhibition of these two pathways was found to be more effective in targeting breast cancer cells (18 (21) , suggesting an association between these two pathways in breast cancer pathogenesis. Consistent with this, we demonstrated a cooperation between active Notch1 and Ras/MAPK pathways in mediating cellular transformation of immortalized breast cells (11) . Interestingly, cleaved (active) Notch1 positive tumors with increased expression of phosphoErk1/2 (active MAPK) showed high node positivity (11), suggesting that Notch-Ras/MAPK cooperation may lead to more aggressive disease.
However, the clinical relevance of Notch-Ras co-activation has not been explored thus far.
In this study we sought to comprehend the consequences of coordinate activation of Notch1 and Ras/MAPK pathways on the survival of breast cancer patients, and the efficacy of their combinatorial inhibition on breast cancer cell lines. We report here that coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor overall survival in breast cancer patients. Majority of such cases encompassed the triple negative breast cancers (TNBC), and were enriched in stem cell markers like Oct4, Nanog and CD44. Simultaneous inhibition of Notch1 and Ras/MAPK with MAb602.101 and MEK inhibitor PD98059, respectively, resulted in a significant reduction in proliferation and survival, and abrogation of mammosphere formation. Importantly, combined inhibition lead to a depletion of the stem-cell like population of breast cancer cells in vitro, and blocked tumor growth in vivo.
Taken together our study demonstrates a nexus between Notch1 and Ras/MAPK signaling in aggressive breast cancers including TNBCs, and provides promising pre-clinical data to target these cancers by combinatorial inhibition of these two pathways. 
Materials and Methods

Cell lines:
Breast cancer cell lines BT-474, MCF-7, MDA-MB-231 and HCC-1806 (obtained from ATCC and no further authentication was performed in the past 6 months) were cultured in DMEM (Sigma) supplemented with 10% FBS (Invitrogen), NBLE cells {described in (22)} and primary cancer tissue derived cells were cultured in serum-free DMEM-F12 media supplemented with growth factors (22) and maintained under standard tissue culture conditions of 37ºC in a humidified incubator.
Immunohistochemistry and tissue samples
Breast cancer tissue sections were obtained from tumor blocks archived in the Department of Pathology at the Kidwai Memorial Institute of Oncology (KMIO). Immunohistochemistry was performed as described previously (11) using cleaved Notch1 specific antibody (2421 V1744, CST) that detects active Notch1 generated following γ-secretase cleavage, pErk1/2 (C33E10; CST), Oct4 (ab19857; AbCam), CD44 (3570S; CST), Nanog (SC-33759; Santa Cruz). Immunohistochemical intensity and distribution were semi quantitatively scored by an experienced pathologist (RVK) using the Allred score method for the nuclear staining, and the membrane and cytoplasmic staining was scored on a relative scale as described previously (11) . For mammosphere formation assays, primary breast tumor tissue was obtained with patient consent from KMIO, as approved by the Medical Ethics Committee (Institutional review board of KMIO) and in compliance with the ethical guidelines of Indian Institute of Science (IISc). The primary tissues were processed as described previously (22 and MAb602.101 (10μg/ml), alone or in combination.
Tumor xenograft assays
Mice experiments were undertaken with prior approval from the Animal Ethics Committee 
Statistical analyses:
Statistical analyses were performed with Fisher's exact test, student's t test, one-way ANOVA and survival analysis using graph-pad prism-5 software. Cox regression analysis was performed with SPSS-16 software. P<0.05 was considered statistically significant.
Results
Coordinate hyper-activation of Notch1 and Ras/MAPK pathways is associated with increased risk of lymph node metastasis, early relapse and poor overall survival
Our earlier study had revealed hyperactivation of Notch1 and Ras/MAPK in high node positive grade III invasive ductal carcinoma (11), suggesting a possible association of NotchRas activation with increased breast tumor aggressiveness. To further explore this, we extended our study to a larger number (115) of grade III ductal carcinoma breast cancer patients, and evaluated their status of Notch1-Ras/MAPK pathways, and additionally, the patient outcome (Table 1A) . To do so, we undertook immunohistochemistry analyses for Notch1 activation using cleaved Notch1 antibody that specifically detects the active form of Notch1 (NICD) generated by gamma secretase cleavage. To detect Ras/MAPK activation, we evaluated the phosphorylation status of Erk (MAPK) using pErk1/2 specific antibodies. (Table 1A) , and additionally showed elevated expression of stemness markers like Oct4, nanog, and CD44
(Supplementary Figure 1B) , further suggesting a possible correlation between Notch1-Ras/MAPK activation, stemness and tumor aggressiveness.
Analogous to several other cancers, the majority of deaths associated with breast cancers are due to metastatic growth and relapse that impairs the functions of vital organs like brain, liver and lungs, thereby presenting a major clinical challenge for achieving disease free survival (25) . Our findings revealing the association of Notch1 and Ras/MAPK activation with aggressive breast cancers ( (Table 1E) . Further, the Kaplan-Meier survival analyses revealed poor overall survival rates in patients with clNotch high pErk high phenotype compared to the 'rest' category ( Figure 1A ).
Interestingly, this trend held true across various breast cancer subtypes including ER/PR+, Her2+, and the highly aggressive TNBCs (Figure 1 Work from our lab and that of others has demonstrated a functional Notch-Ras cooperation in transformation of breast epithelial cells in vitro (11, 20, 21) . The present study revealed an association of elevated activation of Notch1 and pErk1/2 with poor prognosis (Figure 1 , (27, 28) .
However, GSIs target more than 30 physiologically important transmembrane proteins (29) and clinical trials of GSIs have been hindered by considerable gastrointestinal problems experienced by the participants (30) . As an alternative, selective blocking of Notch1 receptor with antibody has been shown to inhibit cancer cell growth in pre-clinical models (31).
Accordingly, we employed an in-house generated anti-Notch1 monoclonal antibody, Figure 3D ). Together, these data indicated that combinatorial inhibition of Notch1 and Ras/MAPK effectively abrogates sphere formation and reduces the CD44 high /24 low/-putative breast cancer stem-like cells.
Combinatorial inhibition of Notch1 and Ras/MAPK causes tumor regression in vivo
To further investigate the potential efficacy of combining Notch1 and Ras/MAPK inhibition, 
Discussion
Hyperactivation of Notch1-Ras/MAPK pathway as prognostic markers in breast cancer
The TNM (tumor size, node, and metastasis) staging system has been the classical and most widely used system to provide prognostic information regarding a patient. Besides TNM, standard predictive markers for breast cancer treatment include hormone receptor expression for endocrine therapy and HER2 status for anti-HER2 therapy (4). There is a further need for better prognostic and predictive markers that can enable improved categorization of breast cancers which can in turn help the correct choice of treatment. With the launch of highthroughput technologies in recent years, a number of multi-gene signatures have been identified (36, 37) that, together with the traditional markers, can serve as better prognostic and predictive markers. Increased Notch receptors, ligands and consequent increase in Notch activity has been reported in breast cancers (11, 38) . Co-expression of Notch1 and Jag1 has been associated with poor prognosis (10) . In this investigation we show that a large number of patients with grade III invasive ductal carcinoma of the breast expressed high levels of 
Combinatorial targeting of Notch1 and Ras/MAPK in breast cancer
Various groups have shown aberrant activation of Notch (10, 17) and Ras pathways (39) in breast cancer and proposed their independent inhibition as strategies to target breast cancer (16, 40) . Emerging studies though show that combinatorial targeting of multiple pathways in cancer is likely to have a better therapeutic effect than solitary approaches (18) . MAb602.101
